# SRRK — Scholar Rock Holding Corp · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** SRRK  
**Sources:** 19  
**Published:** 2026-10-26  
**Canonical:** https://app.k3vl4r.com/research/deep-research-srrk-scholar-rock-holding-corp-catalysts-narrative-risks-9361

---

## Overview

Scholar Rock Holding Corp (SRRK, Nasdaq) is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on rare neuromuscular diseases—chiefly spinal muscular atrophy (SMA)—through its anti-myostatin platform. Its lead asset, apitegromab (marketed as ISEMBYLD / apitegromab-mstn), received U.S. FDA approval in September 2026, shifting the company from a development-stage to a launch-execution narrative [[6]](https://www.ad-hoc-news.de/boerse/news/nebenwerte/raymond-james-raises-target-for-scholar-rock-stock-from-usd-65-00-to-usd-72-00/70228890)[[10]](https://www.morningstar.com/news/business-wire/20260827770946/scholar-rock-to-present-at-upcoming-investor-conferences). The company reports essentially zero commercial revenue and mounting net losses.

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-srrk-scholar-rock-holding-corp-catalysts-narrative-risks-9361 (free to sign up)._